CA3172987A1 - Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer - Google Patents
Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer Download PDFInfo
- Publication number
- CA3172987A1 CA3172987A1 CA3172987A CA3172987A CA3172987A1 CA 3172987 A1 CA3172987 A1 CA 3172987A1 CA 3172987 A CA3172987 A CA 3172987A CA 3172987 A CA3172987 A CA 3172987A CA 3172987 A1 CA3172987 A1 CA 3172987A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- chd1l
- alkyl
- inhibitor
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994259P | 2020-03-24 | 2020-03-24 | |
| US62/994,259 | 2020-03-24 | ||
| US202163139394P | 2021-01-20 | 2021-01-20 | |
| US63/139,394 | 2021-01-20 | ||
| PCT/US2021/023981 WO2021195279A2 (en) | 2020-03-24 | 2021-03-24 | Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3172987A1 true CA3172987A1 (en) | 2021-09-30 |
Family
ID=77892666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3172987A Pending CA3172987A1 (en) | 2020-03-24 | 2021-03-24 | Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4127209A4 (https=) |
| JP (1) | JP2023520330A (https=) |
| CN (1) | CN115667553A (https=) |
| AU (1) | AU2021244209A1 (https=) |
| CA (1) | CA3172987A1 (https=) |
| WO (1) | WO2021195279A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3222727A1 (en) * | 2021-06-17 | 2022-12-22 | The Regents Of The University Of California | E3 ligase inhibitors and methods of use thereof |
| WO2023055763A2 (en) * | 2021-09-30 | 2023-04-06 | The Regents Of The University Of Colorado, A Body Corporate | Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectral cancer |
| CN114457007B (zh) * | 2022-02-28 | 2024-05-28 | 合肥燃音生物科技有限公司 | 一种基于微孔板的均一的单类器官模型及其制备方法 |
| CA3250274A1 (en) * | 2022-05-02 | 2023-11-09 | Eisbach Bio Gmbh | USE OF ALC1 INHIBITORS AND SYNERGY WITH PARPI |
| CN115290774B (zh) * | 2022-07-21 | 2023-07-21 | 重庆医科大学 | 尿苷二磷酸葡萄糖醛酸在制备用于检测肝癌试剂中的应用 |
| WO2024211314A2 (en) * | 2023-04-03 | 2024-10-10 | The Regents Of The University Of Colorado, A Body Corporate | Inhibitors of chd1l and uses thereof |
| WO2025088087A1 (en) | 2023-10-25 | 2025-05-01 | Eisbach Bio Gmbh | A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers |
| AU2024366320A1 (en) * | 2023-10-25 | 2026-04-16 | Eisbach Bio Gmbh | Alc1 inhibitors for use in treating cancer by potentiating the effects of several classes of approved cancer drugs |
| WO2025093706A1 (en) * | 2023-10-31 | 2025-05-08 | Eisbach Bio Gmbh | Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan |
| WO2025129032A1 (en) * | 2023-12-15 | 2025-06-19 | The Regents Of The University Of Colorado, A Body Corporate | Chd1l inhibitors for treating cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060211603A1 (en) * | 2004-08-18 | 2006-09-21 | Vicuron Pharmaceuticals Inc. | Ramoplanin derivatives possessing antibacterial activity |
| CN102792160B (zh) * | 2010-01-08 | 2015-08-19 | 新加坡科技研究局 | 用于治疗癌症的方法和组合物 |
| US20140243403A1 (en) * | 2011-06-03 | 2014-08-28 | The General Hospital Corporation | Treating colorectal, pancreatic, and lung cancer |
| BR112015003655A2 (pt) * | 2012-08-23 | 2017-07-04 | Virostatics Srl | composto; uso de um composto; e composição farmacêutica |
| US20160138114A1 (en) * | 2013-06-19 | 2016-05-19 | The Regents Of The University Of California | Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer |
| CN108976172B (zh) * | 2017-05-31 | 2021-12-07 | 华东师范大学 | 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用 |
| CN109761909B (zh) * | 2019-01-25 | 2022-08-26 | 中国药科大学 | N-(4-(嘧啶-4-氨基)苯基)磺酰胺类抑制剂或其可药用的盐、其制备方法及用途 |
-
2021
- 2021-03-24 CN CN202180037594.1A patent/CN115667553A/zh active Pending
- 2021-03-24 AU AU2021244209A patent/AU2021244209A1/en active Pending
- 2021-03-24 JP JP2022557840A patent/JP2023520330A/ja active Pending
- 2021-03-24 CA CA3172987A patent/CA3172987A1/en active Pending
- 2021-03-24 EP EP21775064.5A patent/EP4127209A4/en active Pending
- 2021-03-24 WO PCT/US2021/023981 patent/WO2021195279A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN115667553A (zh) | 2023-01-31 |
| JP2023520330A (ja) | 2023-05-17 |
| WO2021195279A3 (en) | 2021-11-11 |
| WO2021195279A2 (en) | 2021-09-30 |
| AU2021244209A1 (en) | 2022-11-03 |
| EP4127209A4 (en) | 2024-07-24 |
| EP4127209A2 (en) | 2023-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3172987A1 (en) | Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer | |
| Li et al. | Discovery of N 1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo [2, 3-d] pyrimidin-2-yl) amino) phenyl)-N 8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer | |
| JP2021020957A (ja) | 二官能性分子によって標的化タンパク質分解を誘導する方法 | |
| WO2018133795A1 (zh) | 一种ezh2抑制剂及其用途 | |
| WO2017101803A1 (zh) | 一种新型egfr和alk激酶的双重抑制剂 | |
| WO2025075693A1 (en) | Shp2 degraders for cancer therapy | |
| PH12015502737B1 (en) | Novel fused pyrimidine compound or salt thereof | |
| KR20170003688A (ko) | 단백질 탈아세틸화효소 억제제 및 이중 단백질 탈아세틸화효소-단백질 키나제 억제제로서의 헤테로사이클릭 하이드록삼산 및 그 이용 방법 | |
| AU2021320254A1 (en) | Small molecules for the treatment of autoimmune diseases and cancer | |
| WO2022240966A1 (en) | Compounds and methods for yap/tead modulation and indications therefor | |
| JP2018513214A (ja) | 新規なキナーゼ阻害剤の調製と使用 | |
| US20230103444A1 (en) | Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer | |
| CA2805658C (en) | Combination therapy with mdm2 and egfr inhibitors | |
| JP2015522048A (ja) | 癌の処置および免疫抑制のための併用療法 | |
| Yuan et al. | Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy | |
| EP4337207A1 (en) | Compounds and methods for yap/tead modulation and indications therefor | |
| CA3233398A1 (en) | Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer | |
| US20240016795A1 (en) | Bromodomain inhibitors for androgen receptor-driven cancers | |
| CN112010789A (zh) | 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途 | |
| HK40087586A (zh) | 致癌chd1l的具有抗结肠直肠癌的临床前活性的小分子抑制剂 | |
| US10550114B2 (en) | Kinase inhibitors and their use in cancer therapy | |
| US20250122193A1 (en) | Novel pyridocarbazolium compounds and medical uses thereof | |
| RU2810215C2 (ru) | Ингибиторы рецепторов erbb | |
| WO2019095066A1 (en) | Thienoisoquinolines and their derivatives for targeting tubulin, ch-tog, aurora a kinase, tpx2, cdk5rap2 and/or aspm | |
| Mishra | A New Generation of Isoform Selective Hsp90 Inhibitors: Targeting the Cytosolic Hsp90 Isoforms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220922 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240806 |
|
| C11 | Application revival requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED Effective date: 20250806 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250806 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250811 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250915 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250915 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250919 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250919 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251218 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260224 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260317 |